Audrey R. Odom John, M.D., Ph.D.  odom_a@kids.wustl.edu

Infectious DiseasesPathobiologyMolecular Microbiology

phone: (314) 454-6050

Clinical Interests

As a subspecialist in pediatric infectious diseases, Dr. Odom cares for children with severe or prolonged infections, such as bone and joint infections, meningitis and sepsis. Dr. Odom also has expertise in evaluating and treating infections with unusual presentations, prolonged or recurrent fevers, as well as more unusual infections including atypical bacterial infections, viral infections, tick-borne illnesses, fungal infections, and tuberculosis. Dr. Odom also cares for patients with immunodeficiencies with associated infections.

Education

  • B.S., summa cum laude, Duke University1996
  • Ph.D., Duke University School of Medicine2002
  • M.D., Duke University School of Medicine2003

Training

  • Doctoral research: Duke University Medical Center, Advisor: John York PhD. Nuclear functions of an inositol polyphosphate kinase pathway1998 - 2002
  • Pediatric Residency (Special Alternative Pathway), University of Washington2003 - 2005
  • Fellowship research: University of Washington, Advisor: Wesley Van Voorhis MD PhD. Isoprenoid biosynthesis in the malaria parasite, Plasmodium falciparum2005 - 2008
  • Pediatric Infectious Diseases Fellowship, University of Washington2005 - 2008

Licensure and Board Certification

  • MO, Physician and Surgeon2008
  • ABP, General Pediatrics, # 0955812009
  • ABP Sub-board of Pediatric Infectious Diseases, # 12702011

Honors

  • Contributing member, Faculty of 1000 - Pres
  • Howard Hughes Medical Institute, Forum Fellows Grant1995
  • Phi Beta Kappa1996
  • Alpha Omega Alpha1998
  • American Cancer Society Institutional Research Grant Student Award1999
  • Harold M. Weintraub Graduate Student Award2001
  • Pediatric Infectious Diseases Society Fellowship Award2007
  • Scholar, WU Child Health Research Center of Excellence2008
  • Children's Discovery Institute, New Faculty Recruitment Award2009
  • Doris Duke Charitable Foundation Clinical Scientist Development Award2010
  • Mentor of the year, Washington University2010
  • Co-chair, Drug Discovery for Eukaryotic Pathogens and Parasites session, Keystone Symposium, Drug Discovery for Protozoan Parasites, Santa Fe, NM2012
  • Innovator award, St. Louis Academy of Sciences2012
  • Basil O'Connor Starter Scholar Award, March of Dimes2013
  • Election, Society for Pediatric Research2014
  • Grand Challenge winner and invited speaker, TEDxKC2015
  • Burroughs Wellcome Fund, Investigator in the Pathogenesis of Infectious Diseases (PATH)2016
  • Emerging Leader Award, Duke University School of Medicine alumni association2016
  • American Chemical Society Infectious Diseases, Young Investigator Award2016

Recent Publications view all (27)


Publication Co-Authors

  1. San Jose G, Jackson ER, Haymond A, Johny C, Edwards RL, Wang X, Brothers RC, Edelstein EK, Odom AR, Boshoff HI, Couch RD, Dowd CS. Structure-Activity Relationships of the MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis. ACS Infect Dis. 2016. PMID:27676224  
  2. Kraft TE, Heitmeier MR, Putanko M, Edwards RL, Ilagan MX, Payne MA, Autry JM, Thomas DD, Odom AR, Hruz PW. A novel FRET-based screen in high-throughput format to identify inhibitors of malarial and human glucose transporters. Antimicrob Agents Chemother. 2016. PMID:27736766  
  3. Guggisberg AM, Sundararaman SA, Lanaspa M, Moraleda C, González R, Mayor A, Cisteró P, Hutchinson D, Kremsner PG, Hahn BH, Bassat Q, Odom AR. Whole genome sequencing to evaluate the resistance landscape following antimalarial treatment failure with fosmidomycin-clindamycin. J Infect Dis. 2016. PMID:27443612  
  4. Iannotti LL, Delnatus JR, Odom AR, Eaton JC, Griggs JJ, Brown S, Wolff PB. Determinants of Anemia and Hemoglobin Concentration in Haitian School-Aged Children. Am J Trop Med Hyg. 2015;93(5):1092-8. PMCID:PMC4703262  PMID:26350448  
  5. Kraft TE, Armstrong C, Heitmeier MR, Odom AR, Hruz PW. The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir. Antimicrob Agents Chemother. 2015;59(10):6203-9. PMCID:PMC4576095  PMID:26248369  
  6. Park J, Guggisberg AM, Odom AR, Tolia NH. Cap-domain closure enables diverse substrate recognition by the C2-type haloacid dehalogenase-like sugar phosphatase Plasmodium falciparum HAD1. Acta Crystallogr D Biol Crystallogr. 2015;71(Pt 9):1824-34. PMCID:PMC4556313  PMID:26327372  
  7. Guggisberg AM, Odom AR. Sweet Talk: Regulating Glucose Metabolism in Toxoplasma. Cell Host Microbe. 2015;18(2):142-3. PMID:26269950  
  8. Armstrong CM, Meyers DJ, Imlay LS, Freel Meyers C, Odom AR. Resistance to the antimicrobial agent fosmidomycin and an FR900098 prodrug through mutations in the deoxyxylulose phosphate reductoisomerase gene (dxr). Antimicrob Agents Chemother. 2015. doi:10.1128/AAC.00602-15  PMID:26124156  
  9. Imlay LS, Armstrong CM, Masters MC, Li T, Price KE, Edwards RL, Mann KM, Li LX, Stallings CL, Berry NG, O'Neill PM, Odom AR. Plasmodium IspD (2-C-Methyl-D-erythritol 4-Phosphate Cytidyltransferase), an Essential and Druggable Antimalarial Target. ACS Infect Dis. 2015;1(4):157-167. PMCID:PMC4714788  PMID:26783558  
  10. Kelly M, Su CY, Schaber C, Crowley JR, Hsu FF, Carlson JR, Odom AR. Malaria parasites produce volatile mosquito attractants. MBio. 2015;6(2). doi:10.1128/mBio.00235-15  PMCID:PMC4453533  PMID:25805727  
  11. Imlay L, Odom AR. Isoprenoid metabolism in apicomplexan parasites. Curr Clin Microbiol Rep. 2014;1(3-4):37-50. doi:10.1007/s40588-014-0006-7  PMCID:PMC4399553  PMID:25893156  
  12. Guggisberg AM, Amthor RE, Odom AR. Isoprenoid biosynthesis in Plasmodium falciparum. Eukaryot Cell. 2014;13(11):1348-59. doi:10.1128/EC.00160-14  PMCID:PMC4248697  PMID:25217461  
  13. Guggisberg AM, Park J, Edwards RL, Kelly ML, Hodge DM, Tolia NH, Odom AR. A sugar phosphatase regulates the methylerythritol phosphate (MEP) pathway in malaria parasites. Nat Commun. 2014;5:4467. doi:10.1038/ncomms5467  PMCID:PMC4112465  PMID:25058848  
  14. Odom AR. The triphenylethylenes, a novel class of antifungals. MBio. 2014;5(3):e01126-14. PMCID:PMC4010834  PMID:24781746  
  15. Howe R, Kelly M, Jimah J, Hodge D, Odom AR. Isoprenoid biosynthesis inhibition disrupts Rab5 localization and food vacuolar integrity in Plasmodium falciparum. Eukaryot Cell. 2013;12(2):215-23. doi:10.1128/EC.00073-12  PMID:23223036  
  16. Endo-Streeter S, Tsui MK, Odom AR, Block J, York JD. Structural studies and protein engineering of inositol phosphate multikinase. J Biol Chem. 2012;287(42):35360-9. doi:10.1074/jbc.M112.365031  PMCID:PMC3471723  PMID:22896696  
  17. Odom AR. Five questions about non-mevalonate isoprenoid biosynthesis. PLoS Pathog. 2011;7(12):e1002323. PMCID:PMC3245312  PMID:22216001  
  18. Zhang B, Watts KM, Hodge D, Kemp LM, Hunstad DA, Hicks LM, Odom AR. A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling. Biochemistry. 2011;50(17):3570-7. doi:10.1021/bi200113y  PMCID:PMC3082593  PMID:21438569  
  19. Odom AR, Van Voorhis WC. Functional genetic analysis of the Plasmodium falciparum deoxyxylulose 5-phosphate reductoisomerase gene. Mol Biochem Parasitol. 2010;170(2):108-11. doi:10.1016/j.molbiopara.2009.12.001  PMCID:PMC2814890  PMID:20018214  
  20. Stevenson-Paulik J, Odom AR, York JD. Molecular and biochemical characterization of two plant inositol polyphosphate 6-/3-/5-kinases. J Biol Chem. 2002;277(45):42711-8. doi:10.1074/jbc.M209112200  PMID:12226109  
  21. Davidson RC, Moore TD, Odom AR, Heitman J. Characterization of the MFalpha pheromone of the human fungal pathogen cryptococcus neoformans. Mol Microbiol. 2000;38(5):1017-26. PMID:11123675  
  22. Odom AR, Stahlberg A, Wente SR, York JD. A role for nuclear inositol 1,4,5-trisphosphate kinase in transcriptional control. Science. 2000;287(5460):2026-9. PMID:10720331  
  23. York JD, Odom AR, Murphy R, Ives EB, Wente SR. A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. Science. 1999;285(5424):96-100. PMID:10390371  
  24. Odom AR, Misra UK, Pizzo SV. Nickel inhibits binding of alpha2-macroglobulin-methylamine to the low-density lipoprotein receptor-related protein/alpha2-macroglobulin receptor but not the alpha2-macroglobulin signaling receptor. Biochemistry. 1997;36(41):12395-9. doi:10.1021/bi970806k  PMID:9376342  
  25. Odom A, Muir S, Lim E, Toffaletti DL, Perfect J, Heitman J. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J. 1997;16(10):2576-89. doi:10.1093/emboj/16.10.2576  PMCID:PMC1169869  PMID:9184205  
  26. Odom A, Del Poeta M, Perfect J, Heitman J. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Agents Chemother. 1997;41(1):156-61. PMCID:PMC163677  PMID:8980772  
  27. Martenson CH, Odom A, Sheetz MP, Graham DG. The effect of acrylamide and other sulfhydryl alkylators on the ability of dynein and kinesin to translocate microtubules in vitro. Toxicol Appl Pharmacol. 1995;133(1):73-81. doi:10.1006/taap.1995.1128  PMID:7597712  
Wash U School of Medicine
Children's Hospital St. Louis
Children's Discovery Institute
© 2017 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130